U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Foregut Neuroendocrine Tumor G1

MedGen UID:
232513
•Concept ID:
C1333631
•
Neoplastic Process
Synonym: Foregut Carcinoid Tumor

Definition

A neuroendocrine tumor grade 1 that arises from the lung, thymus, esophagus, stomach, or duodenum. [from NCI]

Professional guidelines

PubMed

A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012.
Maschmeyer G, Mügge LO, Kämpfe D, Kreibich U, Wilhelm S, Aßmann M, Schwarz M, Kahl C, Köhler S, Grobe N, Niederwieser D
J Cancer Res Clin Oncol 2015 Sep;141(9):1639-44. Epub 2015 Mar 15 doi: 10.1007/s00432-015-1954-x. PMID: 25773126

Recent clinical studies

Etiology

Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N
Invest New Drugs 2019 Jun;37(3):573-578. Epub 2018 Sep 28 doi: 10.1007/s10637-018-0669-7. PMID: 30267338
Long-term outcome of endoscopic and surgical resection for foregut neuroendocrine tumors.
Jung HJ, Hong SJ, Han JP, Kim HS, Jeong GA, Cho GS, Kim HK, Ko BM, Lee MS
J Dig Dis 2015 Oct;16(10):595-600. doi: 10.1111/1751-2980.12279. PMID: 26315879
A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012.
Maschmeyer G, Mügge LO, Kämpfe D, Kreibich U, Wilhelm S, Aßmann M, Schwarz M, Kahl C, Köhler S, Grobe N, Niederwieser D
J Cancer Res Clin Oncol 2015 Sep;141(9):1639-44. Epub 2015 Mar 15 doi: 10.1007/s00432-015-1954-x. PMID: 25773126

Diagnosis

Long-term outcome of endoscopic and surgical resection for foregut neuroendocrine tumors.
Jung HJ, Hong SJ, Han JP, Kim HS, Jeong GA, Cho GS, Kim HK, Ko BM, Lee MS
J Dig Dis 2015 Oct;16(10):595-600. doi: 10.1111/1751-2980.12279. PMID: 26315879
A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012.
Maschmeyer G, Mügge LO, Kämpfe D, Kreibich U, Wilhelm S, Aßmann M, Schwarz M, Kahl C, Köhler S, Grobe N, Niederwieser D
J Cancer Res Clin Oncol 2015 Sep;141(9):1639-44. Epub 2015 Mar 15 doi: 10.1007/s00432-015-1954-x. PMID: 25773126
Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study.
Li QL, Zhang YQ, Chen WF, Xu MD, Zhong YS, Ma LL, Qin WZ, Hu JW, Cai MY, Yao LQ, Zhou PH
World J Gastroenterol 2012 Oct 28;18(40):5799-806. doi: 10.3748/wjg.v18.i40.5799. PMID: 23155323Free PMC Article

Therapy

Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N
Invest New Drugs 2019 Jun;37(3):573-578. Epub 2018 Sep 28 doi: 10.1007/s10637-018-0669-7. PMID: 30267338
Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.
Ito T, Honma Y, Hijioka S, Kudo A, Fukutomi A, Nozaki A, Kimura Y, Motoi F, Isayama H, Komoto I, Hisamatsu S, Nakajima A, Shimatsu A
Invest New Drugs 2017 Aug;35(4):499-508. Epub 2017 May 3 doi: 10.1007/s10637-017-0466-8. PMID: 28470558Free PMC Article

Prognosis

Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N
Invest New Drugs 2019 Jun;37(3):573-578. Epub 2018 Sep 28 doi: 10.1007/s10637-018-0669-7. PMID: 30267338
Long-term outcome of endoscopic and surgical resection for foregut neuroendocrine tumors.
Jung HJ, Hong SJ, Han JP, Kim HS, Jeong GA, Cho GS, Kim HK, Ko BM, Lee MS
J Dig Dis 2015 Oct;16(10):595-600. doi: 10.1111/1751-2980.12279. PMID: 26315879

Clinical prediction guides

Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study.
Ida H, Honma Y, Hirano H, Shoji H, Iwasa S, Okita N, Takashima A, Kato K, Fukuda T, Boku N
Invest New Drugs 2019 Jun;37(3):573-578. Epub 2018 Sep 28 doi: 10.1007/s10637-018-0669-7. PMID: 30267338
Long-term outcome of endoscopic and surgical resection for foregut neuroendocrine tumors.
Jung HJ, Hong SJ, Han JP, Kim HS, Jeong GA, Cho GS, Kim HK, Ko BM, Lee MS
J Dig Dis 2015 Oct;16(10):595-600. doi: 10.1111/1751-2980.12279. PMID: 26315879
Endoscopic submucosal dissection for foregut neuroendocrine tumors: an initial study.
Li QL, Zhang YQ, Chen WF, Xu MD, Zhong YS, Ma LL, Qin WZ, Hu JW, Cai MY, Yao LQ, Zhou PH
World J Gastroenterol 2012 Oct 28;18(40):5799-806. doi: 10.3748/wjg.v18.i40.5799. PMID: 23155323Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...